EMEA-000402-PIP03-17-M02

Key facts

Invented name
Vimpat
Active substance
lacosamide
Therapeutic area
Neurology
Decision number
P/0048/2018
PIP number
EMEA-000402-PIP03-17-M02
Pharmaceutical form(s)
  • Film-coated tablet
  • Syrup
  • Solution for infusion
Condition(s) / indication(s)
Treatment of generalised epilepsy and epileptic syndromes
Route(s) of administration
  • Oral use
  • Intravenous use
Contact for public enquiries
UCB Pharma S.A.
Tel. +32 25599454
E-mail: albano.attrice@ucb.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating